This is the authors' abstract. We don't add key points for this paper.
Surgical lung biopsy (SLB) in diffuse parenchymal lung disease (DPLD) has been associated with significant in-hospital mortality (16% for non-elective patients, 1.7% for elective patients, overall 6.4%) [1, 2]. Overall 30-day mortality from SLB is reported at 1.5–4.5% from case series and 2.4% from a large European database [3]. Transbronchial cryobiopsy (TBC) has been proposed as a safer alternative to SLB for diagnosis of DPLD [4]. Existing studies on TBC report immediate procedural complications, but data on mortality at 30 and 90 days is sparse [2]. This study suggests 30- and 90-day mortality after transbronchial cryobiopsy is higher than reported, confirming concerns raised about safety in advanced diffuse lung disease. Keen attention towards patient selection and procedural planning is warranted. http://bit.ly/2ySoZNq
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Pannu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: